Abstract:In this study, a series of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives were designed, synthesized, and evaluated for their biological activities. Upon performing kinase assays, most of the compounds exhibited potent inhibition against JAK2/3 and Aurora A/B with the IC50 values ranging from 0.008 to 2.52 μM. Among these derivatives, compound 10e expressed the most moderate inhibiting activities against all the four kinases with the IC50 values of 0.166 μM (JAK2), 0.057 μM (JAK3), 0.939 μM (Aurora A), and 0.583 μM (Aurora B), respectively. Moreover, most of the derived compounds exhibited potent cytotoxicity against human chronic myeloid leukemia cells K562 and human colon cancer cells HCT116, while compound 10e expressed antiproliferative activities against K562 (IC50 = 6.726μM). According to western blot analysis, compound 10e down-regulated the phosphorylation of STAT3, STAT5, Aurora A, and Aurora B in a dose-dependent manner in K562 and HCT116 cells. Cell cycle analysis revealed that compound 10e inhibited the proliferation of cells by inducing cell cycle arrest in the G2 phase. The molecular modeling suggested that compound 10e could maintain a binding mode similar to the binding mode of AT9832, a common JAK 2/3 and Aurora A/B kinases multi-target kinase inhibitor. Therefore, compound 10e might be a potential agent for cancer therapy deserving further research.

Design, synthesis and bioactivities of 4-(3-sulfonylbenzene) amino-6-formylpyrrole[2, 3-d] pyrimidine derivatives

Synthesis and JAK2 Inhibitory Activities of 4-Phenyl-pyrrolo[2, 3-D] Pyrimidine Derivatives

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Design, Synthesis and Evaluation of Pyrrolo[2,3-D]pyrimidine-phenylamide Hybrids As Potent Janus Kinase 2 Inhibitors.

Design and Synthesis of Novel Pyrrolo[2,3-D]pyrimidine Derivatives As Potent JAK3 and SYK Dual Inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitors

Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.

Synthesis of pyrrolopyrimidines and their JAK3 inhibitory activities

Design, Synthesis, Quantum Chemical Studies and Biological Activity Evaluation of Pyrazole-Benzimidazole Derivatives As Potent Aurora A/B Kinase Inhibitors.

Design, Synthesis, and Biological Activity of Phenyl-Pyrazole Derivatives As BCR–ABL Kinase Inhibitors

Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.

Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1h)-pyrazole Derivatives As JAKs Inhibitors.

Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.

Design, Synthesis and Bioevaluation of N-trisubstituted Pyrimidine Derivatives As Potent Aurora A Kinase Inhibitors

Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

Design, Synthesis and Activity Study of Pyridine Derivatives as Highly Effective and Selective TYK2 Inhibitors.

Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.

Design, synthesis and biological evaluation of novel N-(methyl-d3) pyridazine-3-carboxamide derivatives as TYK2 inhibitors

Novel 2,4-Diarylaminopyrimidine Derivatives Containing Pyridine Moiety: Design, Synthesis, Crystal Structure and Biological Evaluation

Design, Synthesis and Biological Evaluation of Pyridin-3-Yl Pyrimidines As Potent Bcr-Abl Inhibitors